Lung cancer is one of the most common types of cancer and the leading cause of cancer-related deaths worldwide. A major factor related with the high mortality rate of lung cancer patients is the late diagnosis of the disease. So, the identification and characterization of new epigenetic marks and mechanisms may contribute to better diagnose and treat lung cancer. In this chapter we review the epigenetic mechanisms involved in lung cancer, including DNA methylation, histone posttranslational modification and noncoding RNAs. The chapter focuses on biomarkers for diagnostic, prognostic and response to treatment. Finally, thanks to the reversible nature of epigenetic marks, we provide not only information about the therapeutic targets identified in preclinical studies but also drugs which are being evaluated for lung cancer in clinical trials. Epigenetics translated to personalized medicine will help to develop new tools to guide decisions made by the oncologist regarding the proper treatment of lung cancer. READ ARTICLE
Epigenetics in Precision Medicine DOI:10.1016/B978-0-12-823008-4.00007-X
Authors: Alejandro Cardona-Monzonís, Ángel L. Ortega, Julian Carretero, José Luis García-Giménez, Salvador Mena-Mollá
